Memantine for dementia.

By S. A. Areosa, F. Sherriff, R. McShane. Cochrane Database of Systematic Reviews, 2005

1,000 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/053798061981d5b9b3f06a30108cbaa0a1d64b37

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. K. Seppi
2. D. Holtzman
3. John Hardy
4. C. Lane
5. A. Goate
6. M. Coelho
7. John C. Morris
8. R. Katzenschlager

Citations in the corpus

• The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the Non-Motor Symptoms of Parkinson's Disease (2011, methodology): “A recent meta-analysis by the Cochrane Dementia and Cognitive Improvement Group found that memantine was well tolerated in patients with Alzheimer’s disease and vascular dementia.(50) Therefore memantine is considered to have an acceptable risk without a need for specialized monitoring.”
• Therapeutics of Alzheimer's disease: Past, present and future. (2014, background): “At the dose commonly used (20 mg/kg body weight), memantine improves overall functioning status, improves cognitive abilities and activities of daily living, slows down functional decline and decreases worsening of mood and behavior (Hellweg et al., 2012; McShane et al., 2006).”
• Alzheimer Disease: An Update on Pathobiology and Treatment Strategies (2019, unknown): “Meta-analysis confirms the efficacy of memantine in moderate-to-severe AD on measures of cognition, activities of daily living (ADL) and neuropsychiatric symptoms (McShane et al., 2006).”
• Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse. (2007, result): “All studies showed a strong tendency for improvement by memantine treatment over placebo, while three demonstrated clear statistical significance, and the beneficial effects on cognition were also obvious in various meta analyses (Doody et al., 2005; McShane et al., 2006).”
• Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases. (2018, background): “…believed to work by suppressing glutamatemediated excitotoxicity, has been shown to reduce clinical deterioration on several scales in patients with moderate-to-severe AD compared with controls (Howard et al. 2012; Reisberg et al. 2003), but not in patients with mild disease (McShane et al. 2006).”
• Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline (2008, result): “Other reviews on memantine (83, 84) concur with the findings of this systematic review.”
• Donepezil and memantine for moderate-to-severe Alzheimer's disease. (2012, unknown): “3 to <6 mo 3 (4) 4 (5) 3 (4) 4 (5) 14 (5)”
• Current and future treatments for Alzheimer’s disease (2013, background): “A systemic review of double-blind, parallel-group, RCT studies of memantine showed improvement in cognition, ADL and behaviors in people with moderate to severe AD after 6 months of use [McShane et al. 2006].”
• Alzheimer's disease (2018, background): “Memantine has been shown to have a small but clinically appreciable benefit on cognition and functional decline in patients with moderate to severe AD, with some evidence that it reduces the likelihood of patients developing agitation [63].”
• Alzheimer’s Disease: The Challenge of the Second Century (2011, background): “There are also very modest symptomatic benefits, although limited to persons with moderate to severe AD, with memantine, a drug that modulates the N-methyl-D-aspartate (NMDA) subtype of glutamate receptors (34), among other properties.”
• Post-stroke cognitive impairment: epidemiology, mechanisms and management. (2014, methodology): “However, the meta-analysis on the two trials above suggested that the benefits in cognition and behavior were not supported by clinical global measures (97).”